A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

David M. Jackman,Opeyemi Jegede,Marjorie G. Zauderer,Edith P. Mitchell,James A. Zwiebel,Robert Gray,Shuli Li,Lisa M. McShane,Larry Rubinstein,David R. Patton,Paul Williams,Stanley R. Hamilton,Barbara A. Conley,Carlos L. Arteaga,Lyndsay Harris,Peter J. ODwyer,Alice P. Chen,Keith T. Flaherty

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

2021

David M. Jackman
Opeyemi Jegede
Marjorie G. Zauderer
Edith P. Mitchell
James A. Zwiebel
Robert Gray
Shuli Li
Lisa M. McShane
Larry Rubinstein
David R. Patton
Paul Williams
Stanley R. Hamilton
Barbara A. Conley
Carlos L. Arteaga
Lyndsay Harris
Peter J. ODwyer
Alice P. Chen
Keith T. Flaherty

3087Background: The NCI-MATCH trial assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma to targeted therapies based on genetic alterations identified in tumor biopsies. Neurofi...

Keywords:

Internal medicine
Medicine
Defactinib
in patient
Phases of clinical research
Oncology
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations